The business model of Natco Pharma is such that it targets launching generics of large and niche limited competition products in the US. that are going to turn off patent. Natco generally does so ...

Natco Pharma plans to launch its CTPR products very shortly, which is estimated to have a market size of over ₹2,000 crore in India. Natco Pharma shares surged after the drug maker unveiled the first ...

During the quarter, contribution from the export formulation business was lower; however, the company expects healthy ...

Lupin and Natco receive US FDA approval for generic Tracleer tablets for oral suspension: Our Bureau, Mumbai Monday, February 10, 2025, 15:45 Hrs [IST] Global pharma major Lupin L ...

Hyderabad: NATCO Pharma Limited has announced final approval of its Abbreviated New Drug Application (ANDA) for Bosentan ...

Hyderabad: NATCO Pharma Limited, an Indian pharmaceutical company, has announced the approval of its Abbreviated New Drug Administration (ANDA) for Everolimus tablets for oral suspension ...

In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.Natco Pharma is also ...

Stock analysts noted Natco Pharma’s missed consensus Q3 estimates on both revenue and Ebitda margin fronts due to lack of ...

Natco Pharma Ltd. is a Public Limited Listed ... medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 3568.90 Cr. and Equity Capital is Rs. 35.80 Cr.